Senti Biosciences Holdings
SNTI
25 hedge funds and large institutions have $5.02M invested in Senti Biosciences Holdings in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 6 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.06% less ownership
Funds ownership: 2.76% → 2.7% (-0.06%)
11% less funds holding
Funds holding: 28 → 25 (-3)
34% less capital invested
Capital invested by funds: $7.64M → $5.02M (-$2.62M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$77.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$26.3K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$21.7K |
| 4 |
TM
Triatomic Management
Palo Alto,
California
|
+$6.88K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$138 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$169K |
| 2 |
VF
Virtu Financial
New York
|
-$22K |
| 3 |
Morgan Stanley
New York
|
-$11.7K |
| 4 |
Renaissance Technologies
New York
|
-$11K |
| 5 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
-$8.28K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Renaissance Technologies
New York
| – | -$11K | -1,730 | Closed |
|
|
27
Morgan Stanley
New York
| – | -$11.7K | -1,700 | Closed |
|
|
28
CIBC Asset Management
Toronto,
Ontario, Canada
| – | -$8.28K | -1,320 | Closed |
|
|
GSC
29
Ground Swell Capital
Folly Beach,
South Carolina
| – | -$7.88K | -1,265 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$2.12K | -338 | Closed |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$323 | -47 | -48% |
|
SNTI Hedge Fund Activity: Q3 2023 in Review
25 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Senti Biosciences Holdings (SNTI) for Q3 2023, worth a combined $5.02M — down 34% from $7.64M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SNTI and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was TD Asset Management, adding an estimated $77.9K. The largest seller was T. Rowe Price Associates, cutting an estimated $169K.
- 25 institutional investors held Senti Biosciences Holdings (SNTI) as of Q3 2023, down from 28 in Q2 2023.
- Funds reported $5.02M of Senti Biosciences Holdings stock for Q3 2023, down 34% quarter-over-quarter.
- 3 funds opened new Senti Biosciences Holdings positions in Q3 2023 and 6 closed out, a net change of -3 holders.
- The largest Senti Biosciences Holdings buyer in Q3 2023 was TD Asset Management, an estimated $77.9K added.
- The largest Senti Biosciences Holdings seller in Q3 2023 was T. Rowe Price Associates, an estimated $169K sold.
Based on aggregated 13F filings for Q3 2023.